Background: NTM(Nontuberculous mycobacteria) pulmonary disease is increasing worldwidely, however the diagnosis and treatment of NTM pulmonary disease still has multiple obstacles. The initiation of treatment is not necessary for all patients with NTM pulmonary disease. In addition, the drugs for treatment of NTM pulmonary disease is not enough. objective. The aim of this prospective registry for Nontuberculous mycobacterial pulmonary disease is to register the NTM pulmonary patients and analysis of the treatment outcome based on the species and to collect the blood and urine samples from the patients for exploring the biomarker for diagnosis and monitoring the NTM pulmonary disease and collect the nontuberculous mycobacterium. Methods: 1. informed consents 2. register in cohort and collect the clinical information and serum, plasma, urine and mycobacteria 3. follow up 6 months to 1year based on the clinical situation Analysis: 1. treatment outcome based on NTM-NET consensus statement 2. exploration of biomarker for progression and monitoring of treatment response
Study Type
OBSERVATIONAL
Enrollment
114
Department of Internal Medicine, Yonsei University College of Medicine Division of Pulmonology, Severance Hospital, Yonsei University Health System
Seoul, South Korea
treatment outcome based on NTM-NET consensus statement
1. For patients who need the treatment for NTM pulmonary disease : treatment outcome based on the NTM -NET consensus : microbiologic results, clinical symptoms and radiologic results 2. For patients who don't need the treatment for NTM pulmonary disease : progression of NTM-PD defined by clinical, microbiotic and radiologic results.
Time frame: At the end of the treatment or 12months after treatment
biomarker for disease progression: RNA sequence analysis
exploration for various biomarkers with RNA sequence analysis
Time frame: at the beginning of the treatment
biomarker for disease progression: metabolomic analysis
exploration for various biomarkers with metabolomic analysis
Time frame: at the beginning of the treatment
biomarker for disease progression: RNA sequence analysis
exploration for various biomarkers with RNA sequence analysis
Time frame: at the end of the treatment (through study completion, an average of 12 to 15month after treatment)
biomarker for disease progression: metabolomic analysis
exploration for various biomarkers with metabolomic analysis
Time frame: at the end of the treatment (through study completion, an average of 12 to 15month after treatment)
biomarker for monitoring of treatment response: RNA sequence analysis
exploration for various biomarkers with RNA sequence analysis
Time frame: at the beginning of the treatment
biomarker for monitoring of treatment response: metabolomic analysis
exploration for various biomarkers with metabolomic analysis
Time frame: at the beginning of the treatment
biomarker for monitoring of treatment response: RNA sequence analysis
exploration for various biomarkers with RNA sequence analysis
Time frame: at the end of the treatment (through study completion, an average of 12 to 15month after treatment)
biomarker for monitoring of treatment response: metabolomic analysis
exploration for various biomarkers with metabolomic analysis
Time frame: at the end of the treatment (through study completion, an average of 12 to 15month after treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.